
Aspergillosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Aspergillosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aspergillosis - Drugs In Development, 2022, provides an overview of the Aspergillosis (Infectious Disease) pipeline landscape.
Aspergillosis is an infection or allergic response due to the Aspergillus fungus. Symptoms include cough, fever, headaches, general ill feeling (malaise), weight loss and chest pain. The predisposing factors include weakened immune system, low white blood cell level, asthma and long-term corticosteroid therapy. Treatment includes oral corticosteroids, antifungal and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aspergillosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Aspergillosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Aspergillosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 6, 2, 3, 19 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 5 and 3 molecules, respectively.
Aspergillosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aspergillosis - Drugs In Development, 2022, provides an overview of the Aspergillosis (Infectious Disease) pipeline landscape.
Aspergillosis is an infection or allergic response due to the Aspergillus fungus. Symptoms include cough, fever, headaches, general ill feeling (malaise), weight loss and chest pain. The predisposing factors include weakened immune system, low white blood cell level, asthma and long-term corticosteroid therapy. Treatment includes oral corticosteroids, antifungal and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aspergillosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Aspergillosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Aspergillosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 6, 2, 3, 19 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 5 and 3 molecules, respectively.
Aspergillosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Aspergillosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Aspergillosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Aspergillosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Aspergillosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Aspergillosis (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Aspergillosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Aspergillosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
99 Pages
- Introduction
- Global Markets Direct Report Coverage
- Aspergillosis – Overview
- Aspergillosis – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Aspergillosis – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Aspergillosis – Companies Involved in Therapeutics Development
- AbGenics Life Sciences Pvt Ltd
- Argenx SE
- Basilea Pharmaceutica Ltd
- Bio-Synectics Inc
- Biosergen AS
- Cellix Bio Pvt Ltd
- Cidara Therapeutics Inc
- CSPC Pharmaceutical Group Ltd
- F2G Ltd
- FUJIFILM Toyama Chemical Co Ltd
- Galephar Pharmaceutical Research Inc
- Shaanxi Synthetic Pharmaceutical Co Ltd
- Immupharma Plc
- Jiangsu Aosaikang Pharmaceutical Co Ltd
- Matinas BioPharma Holdings Inc
- Merck & Co Inc
- Molecular Express Inc
- Mycovia Pharmaceuticals Inc
- Nanomerics Ltd
- Novabiotics Ltd
- Pfizer Inc
- Pulmocide Ltd
- Pulmonomy Inc
- Regeneron Pharmaceuticals Inc
- Satellos Bioscience Inc
- Scynexis Inc
- Stadius Biopharma LLC
- TFF Pharmaceuticals Inc
- Trilogy Therapeutics Inc
- Visterra Inc
- Aspergillosis – Drug Profiles
- amphotericin B – Drug Profile
- amphotericin B – Drug Profile
- amphotericin B – Drug Profile
- amphotericin B – Drug Profile
- Antibody for Aspergillosis – Drug Profile
- APX-001A – Drug Profile
- ARGX-118 – Drug Profile
- Aspergillus fumigatus vaccine – Drug Profile
- BioAMP-B – Drug Profile
- BS-105 – Drug Profile
- BSG-005 – Drug Profile
- caspofungin acetate – Drug Profile
- celastrol – Drug Profile
- Cellular Immunotherapy for Fungal Infections – Drug Profile
- CLXIFN-59 – Drug Profile
- CLXPUL-5910E – Drug Profile
- CLXPUL-597E – Drug Profile
- dupilumab – Drug Profile
- EVQ-218 – Drug Profile
- fosmanogepix – Drug Profile
- HCP-002 – Drug Profile
- ibrexafungerp citrate – Drug Profile
- isavuconazonium sulfate – Drug Profile
- isavuconazonium sulfate – Drug Profile
- itraconazole – Drug Profile
- MDN-0018 – Drug Profile
- Monoclonal Antibodies for Fungal Infections – Drug Profile
- Monoclonal Antibody for Aspergillosis – Drug Profile
- NP-339 – Drug Profile
- olorofim – Drug Profile
- opelconazole – Drug Profile
- PC-1244 – Drug Profile
- Pentavalent-Specific T Cells (penta-STs) – Drug Profile
- posaconazole – Drug Profile
- Recombinant Protein for Aspergillosis – Drug Profile
- rezafungin acetate – Drug Profile
- Small Molecule for Aspergillosis – Drug Profile
- Small Molecules for Fungal Infections – Drug Profile
- T-2307 – Drug Profile
- TCPMY-116 – Drug Profile
- TCPMY-119 – Drug Profile
- Vaccine to Target Glucosylceramide for Fungal Infections – Drug Profile
- VIS-FNG – Drug Profile
- voriconazole – Drug Profile
- VT-1598 – Drug Profile
- Aspergillosis – Dormant Projects
- Aspergillosis – Discontinued Products
- Aspergillosis – Product Development Milestones
- Featured News & Press Releases
- Sep 08, 2022: TFF Pharmaceuticals announces presentation of patient data with Voriconazole Inhalation Powder (TFF VORI) at the 15th International Congress on Lung Transplantation
- Jun 24, 2022: Basilea announces approval for additional formulation of antifungal Cresemba (isavuconazole) in China
- Jun 17, 2022: Cresemba sales in Asia Pacific region trigger sales milestone payment to Basilea from Pfizer
- Jan 12, 2022: Basilea announces approval of antifungal Cresemba(isavuconazole) for invasive aspergillosis in China
- Jan 07, 2022: Strong Cresemba (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million sales milestone payment to Basilea
- Dec 08, 2021: Continued strong Cresemba (isavuconazole) sales by Pfizer trigger USD 10 million sales milestone payment to Basilea
- Nov 29, 2021: SCYNEXIS to host Ibrexafungerp hospital pipeline update Call and KOL webcast for investors on December 6
- Nov 11, 2021: CHMP recommended extensions of indication for Noxafil
- Nov 08, 2021: TFF Pharmaceuticals announces completion of dosing of phase 1b study for voriconazole inhalation powder in mild to moderate asthma patients
- Nov 08, 2021: TFF Pharmaceuticals announces completion of dosing of phase 1b study for voriconazole inhalation powder in mild to moderate asthma patients
- Sep 30, 2021: Basilea’s partner Asahi Kasei Pharma filed New Drug Application for the marketing authorization of isavuconazole in Japan
- Sep 27, 2021: Obtained additional approval for the indication of Noxafil, a treatment for deep-seated fungal diseases
- Sep 16, 2021: CHMP recommended extensions of Noxafil indication
- Sep 15, 2021: Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA
- Jul 27, 2021: Cidara Therapeutics to present new data for Rezafungin at the International Society for Human and Animal Mycology (ISHAM) Asia Congress
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Aspergillosis, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Universities/Institutes, 2022
- Table 5: Products under Development by Companies, 2022
- Table 6: Products under Development by Companies, 2022 (Contd..1)
- Table 7: Products under Development by Companies, 2022 (Contd..2)
- Table 8: Products under Development by Universities/Institutes, 2022
- Table 9: Number of Products by Stage and Target, 2022
- Table 10: Number of Products by Stage and Mechanism of Action, 2022
- Table 11: Number of Products by Stage and Route of Administration, 2022
- Table 12: Number of Products by Stage and Molecule Type, 2022
- Table 13: Aspergillosis – Pipeline by AbGenics Life Sciences Pvt Ltd, 2022
- Table 14: Aspergillosis – Pipeline by Argenx SE, 2022
- Table 15: Aspergillosis – Pipeline by Basilea Pharmaceutica Ltd, 2022
- Table 16: Aspergillosis – Pipeline by Bio-Synectics Inc, 2022
- Table 17: Aspergillosis – Pipeline by Biosergen AS, 2022
- Table 18: Aspergillosis – Pipeline by Cellix Bio Pvt Ltd, 2022
- Table 19: Aspergillosis – Pipeline by Cidara Therapeutics Inc, 2022
- Table 20: Aspergillosis – Pipeline by CSPC Pharmaceutical Group Ltd, 2022
- Table 21: Aspergillosis – Pipeline by F2G Ltd, 2022
- Table 22: Aspergillosis – Pipeline by FUJIFILM Toyama Chemical Co Ltd, 2022
- Table 23: Aspergillosis – Pipeline by Galephar Pharmaceutical Research Inc, 2022
- Table 24: Aspergillosis – Pipeline by Shaanxi Synthetic Pharmaceutical Co Ltd, 2022
- Table 25: Aspergillosis – Pipeline by Immupharma Plc, 2022
- Table 26: Aspergillosis – Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, 2022
- Table 27: Aspergillosis – Pipeline by Matinas BioPharma Holdings Inc, 2022
- Table 28: Aspergillosis – Pipeline by Merck & Co Inc, 2022
- Table 29: Aspergillosis – Pipeline by Molecular Express Inc, 2022
- Table 30: Aspergillosis – Pipeline by Mycovia Pharmaceuticals Inc, 2022
- Table 31: Aspergillosis – Pipeline by Nanomerics Ltd, 2022
- Table 32: Aspergillosis – Pipeline by Novabiotics Ltd, 2022
- Table 33: Aspergillosis – Pipeline by Pfizer Inc, 2022
- Table 34: Aspergillosis – Pipeline by Pulmocide Ltd, 2022
- Table 35: Aspergillosis – Pipeline by Pulmonomy Inc, 2022
- Table 36: Aspergillosis – Pipeline by Regeneron Pharmaceuticals Inc, 2022
- Table 37: Aspergillosis – Pipeline by Satellos Bioscience Inc, 2022
- Table 38: Aspergillosis – Pipeline by Scynexis Inc, 2022
- Table 39: Aspergillosis – Pipeline by Stadius Biopharma LLC, 2022
- Table 40: Aspergillosis – Pipeline by TFF Pharmaceuticals Inc, 2022
- Table 41: Aspergillosis – Pipeline by Trilogy Therapeutics Inc, 2022
- Table 42: Aspergillosis – Pipeline by Visterra Inc, 2022
- Table 43: Aspergillosis – Dormant Projects, 2022
- Table 44: Aspergillosis – Dormant Projects, 2022 (Contd..1)
- Table 45: Aspergillosis – Dormant Projects, 2022 (Contd..2)
- Table 46: Aspergillosis – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Aspergillosis, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Routes of Administration, 2022
- Figure 10: Number of Products by Molecule Types, 2022
- Figure 11: Number of Products by Stage and Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.